| __timestamp | Amneal Pharmaceuticals, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 79529000 |
| Thursday, January 1, 2015 | 109679000 | 91224000 |
| Friday, January 1, 2016 | 118757000 | 102413000 |
| Sunday, January 1, 2017 | 109046000 | 146987000 |
| Monday, January 1, 2018 | 230435000 | 213695000 |
| Tuesday, January 1, 2019 | 289598000 | 342000000 |
| Wednesday, January 1, 2020 | 326727000 | 661000000 |
| Friday, January 1, 2021 | 365504000 | 1283000000 |
| Saturday, January 1, 2022 | 399700000 | 2676000000 |
| Sunday, January 1, 2023 | 429675000 | 3297000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Amneal Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, reaching approximately $3.3 billion in 2023. In contrast, Amneal Pharmaceuticals, Inc. experienced a more modest rise of around 400%, with expenses peaking at $429 million in the same year.
This stark difference highlights Genmab's aggressive expansion and investment in administrative capabilities, while Amneal maintains a more conservative approach. Such insights are invaluable for investors and industry analysts seeking to understand the strategic priorities and operational efficiencies of these pharmaceutical giants. As the industry continues to grow, monitoring these trends will be key to predicting future market dynamics.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.